The Concept of the Polypill in the Prevention of Cardiovascular Disease

A Polypill for All? Critical Review of the Polypill Literature for Primary Prevention of Cardiovascular Disease and Stroke

(2012) Katherine M Carey et al.   ANNALS OF PHARMACOTHERAPY

Strategies for Multivessel Revascularization in Patients with Diabetes

(2012) Michael E. Farkouh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Polypill Crossover Trial in People Aged 50 and Over

(2012) David S. Wald et al.   PLoS One

Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects

(2011) Paul Muntner et al.   AMERICAN HEART JOURNAL

The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives

(2011) Ginés Sanz et al.   AMERICAN HEART JOURNAL

Effect of Use of Combination Evidence-Based Medical Therapy After Acute Coronary Syndromes on Long-Term Outcomes

(2011) Rony Lahoud et al.   AMERICAN JOURNAL OF CARDIOLOGY

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

(2011) Salim Yusuf et al.   LANCET

An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk

(2011)   PLoS One

Preservation of Bioavailability of Ingredients and Lack of Drug-Drug Interactions in a Novel Five-Ingredient Polypill (Polycap™)

(2010) Anil Patel et al.   American Journal of Cardiovascular Drugs

The Polypill in the Prevention of Cardiovascular Diseases

(2010) Eva Lonn et al.   CIRCULATION

Heart Disease and Stroke Statistics—2011 Update

(2010) Véronique L. Roger et al.   CIRCULATION

A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors

(2010) F. Malekzadeh et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

(2009) Kornelia Kotseva et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

(2009)   LANCET

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

(2009)   LANCET

Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease

(2008) P. Michael Ho et al.   AMERICAN HEART JOURNAL

Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk

(2008) Jacoba P. Greving et al.   CIRCULATION

Issues to consider in the pharmaceutical development of a cardiovascular polypill

(2008) Antonio Guglietta et al.   Nature clinical practice. Cardiovascular medicine